Mining TCGA and Genomics of Drug Sensitivity in Cancer (GDSC) databases showed that NOP56 expression is negatively correlated with that of mTOR pathway genes in patients with KRAS-mutant lung adenocarcinomas (Fig. 3E) and that NOP56 mRNA levels are a predictive marker of sensitivity (IC50) to rapamycin in KRAS-mutant cancer cell lines but not in KRAS-wild-type cancer cells (Fig. 3F). The gene discussed is MTOR; the disease is cancer.